Synbiotic SE
SBX | F
Overview
Corporate Details
- ISIN(s):
- DE000A351MG9 (+6 more)
- LEI:
- 48510041U2G1IWA3R418
- Country:
- Germany
- Address:
- Münsterstr. 336, 40470 Düsseldorf
- Website:
- https://www.synbiotic.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
SynBiotic SE is a leading European publicly listed corporate group focused on the industrial hemp and cannabis market. The company pursues a pan-European "buy and build" investment strategy to create a vertically integrated platform. Its operations encompass the entire value chain, from cultivation, research, and development to the production, distribution, and retail of industrial hemp, medical cannabis, and recreational cannabis products. By investing in and integrating promising ventures, SynBiotic SE aims to build a comprehensive ecosystem to capitalize on the growth of the European cannabis sector.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Synbiotic SE.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-14 11:19 |
Regulatory News Service
Across the pond: SYNBIOTIC attracts international investors with established in…
|
English | 10.2 KB | |
| 2025-07-29 12:54 |
Business and Financial Review
Revenue expected to triple by 2027: Focus on growth markets for medical cannabi…
|
English | 10.9 KB | |
| 2025-06-11 11:48 |
Regulatory News Service
Successful roadshow continues: SYNBIOTIC keeps expanding its presence in the ca…
|
English | 9.3 KB | |
| 2025-04-23 09:24 |
Director's Dealing
SYNBIOTIC SE: HempConsult GmbH, Lending (free of charge) of 50,000 shares as p…
|
English | 6.1 KB | |
| 2025-04-18 14:14 |
Share Issue/Capital Change
IRIS Capital invests in SYNBIOTIC's growth strategy
|
English | 8.7 KB | |
| 2025-04-17 13:21 |
Capital/Financing Update
SYNBIOTIC SE: STRATEGISCHE PARTNERSCHAFT MIT IRIS CAPITAL INVESTMENT
|
German | 6.8 KB | |
| 2025-04-01 15:13 |
Regulatory News Service
SYNBIOTIC presents medical cannabis as a pastille for the German market for the…
|
English | 8.7 KB | |
| 2025-03-14 11:14 |
Regulatory News Service
Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis B…
|
English | 11.3 KB | |
| 2025-03-13 11:14 |
Regulatory News Service
Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis B…
|
English | 11.3 KB | |
| 2025-01-11 11:44 |
M&A Activity
SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for …
|
English | 10.0 KB | |
| 2025-01-10 11:44 |
M&A Activity
SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for …
|
English | 10.0 KB | |
| 2024-12-19 13:06 |
Regulatory News Service
Trend-setting decontamination: SYNBIOTIC and GOC NEXUS set the gold standard fo…
|
English | 10.2 KB | |
| 2024-12-18 13:06 |
Regulatory News Service
Trend-setting decontamination: SYNBIOTIC and GOC NEXUS set the gold standard fo…
|
English | 10.2 KB | |
| 2024-12-14 16:45 |
Regulatory News Service
SYNBIOTIC SE geht mit der GOC NEXUS OPERATIONS GMBH strategische Partnerschaft …
|
German | 6.8 KB | |
| 2024-12-13 12:24 |
Regulatory News Service
SYNBIOTIC SE: Einbringung der CannaCare Health GmbH wird nicht durchgefuhrt.
|
German | 6.4 KB |
Automate Your Workflow. Get a real-time feed of all Synbiotic SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Synbiotic SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-13 | Otto, Frank | Supervisory board | Other | None | 1,085,723.60 EUR |
| 2023-11-28 | Kruse, Daniel | Other | Buy | None | 19,794.19 EUR |
| 2023-11-28 | Kruse, Daniel | Other | Buy | None | 297.00 EUR |
| 2023-10-23 | Otto, Frank | Supervisory board | Other | None | 354,474.00 EUR |
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
